Toxicity 

Product Safety Laboratories, Dayton, NJ, conducted the following studies.

Activated Solution

The tests were conducted using the activated 2L500 solution, nominally 500 ppm chlorine dioxide. Selective Micro Technologies provided product that actually produced around 700 ppm to insure that the studies were conducted using the highest concentrations that would be achieved if the product were activated according to instructions.

Acute Oral Toxicity: Protocol No. P320 EPA (FIFRA) and FDA. The single dose acute oral LD50 of the activated solution is greater than 5,000 mg/kg of bodyweight in male and female rats. The product is not considered toxic via the oral route.

Dermal Sensitization: Protocol No. P328 EPA (FIFRA). The activated solution is not considered to be a contact sensitizer.

Acute Inhalation Toxicity: Protocol No. P330 EPA (FIFRA). The LC50 of the activated solution is greater than 2.07 mg/L in male and female rats. The activated solution is not considered to be toxic via the inhalation route.

Primary Eye Irritation: Protocol No. P324, EPA (FIFRA) and OECD. The activated solution is classified as minimally irritating to the eye.

Primary Skin Irritation: Protocol No. P326, EPA (FIFRA) and OECD. The activated solution is classified as slightly irritating to the skin.

Dry, Unactivated Product:

Primary Skin Irritation: Protocol No. P326, EPA (FIFRA) and FDA. The mixture of dry chemicals is classified as severely irritating to the skin.

Acute Dermal Toxicity: Protocol No. P322, EPA (FIFRA) and FDA. The single dose dermal LD50 of the mixture of dry chemicals is greater than 5,000mg/kg of body weight in male and female rats. Therefore, the mixture of dry chemicals is not considered toxic via the dermal route.

Acute Oral Toxicity: Protocol No. P320, EPA (FIFRA) and FDA. For the mixture of dry chemicals, the acute oral defined LD50 is 1,200 mg/kg of bodyweight in male and female rats.

Primary Eye Irritation: Protocol No. P324, EPA (FIFRA), OECD and FDA. The mixture of dry chemicals from a single instillation via the ocular route is severely irritating to the eye.